Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zicam Multi-Symptom refers to a line of over-the-counter (OTC) conventional pharmaceutical products developed by Matrixx Initiatives (now owned by Church & Dwight) for the relief of common cold and influenza symptoms. Unlike the brand's flagship homeopathic zinc-based remedies, the Multi-Symptom formulations utilize standard small molecule active ingredients. The nighttime liquid formulation typically contains acetaminophen (an analgesic and antipyretic), dextromethorphan hydrobromide (an antitussive), and doxylamine succinate (a sedating antihistamine). These components work synergistically to reduce fever, alleviate minor aches and pains, suppress cough, and relieve symptoms like runny nose and sneezing. Daytime versions generally omit the sedating antihistamine to prevent drowsiness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zicam Multi-Symptom.